An observational study in Healthcare Associated Infection, Critically Ill and Endotracheal Tube, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by Centre Hospitalier Universitaire Dijon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Cross Infection with a site in France — 8 open to participants now, 9 under way, 1 of them phase 3. Cross Infection · France.
Among the 47 studies in Cross Infection with a site in France, this one is the 18th largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2024, is one of 24 observational ones, and was the 40th registered.
287 studies on the registry are indexed under Cross Infection; 47 are open to participants now.
Browse Cross Infection studies →8 of the 47 studies in Cross Infection with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+ · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 27 Cross Infection studies recruiting now, 23 (85%) set no upper age limit and 2 (7%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 80 is below the median of 366 across 116 observational studies indexed under Cross Infection.
Median enrollment 244 across the 23 interventional studies, 496 across the 24 observational. Of the 31 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 47 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire Dijon is the lead sponsor of 499 studies on the registry; 103 are open to participants now.
Centre Hospitalier Universitaire Dijon has 1 study filed under Cross Infection — fewer than ten, so there is no comparison to draw.
4 of the studies in Cross Infection with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05719259European Clinical Research Alliance for Infectious Diseases (ECRAID)Perpetual Observational Study - Ventilator Associated Pneumonia | 2026-12-01 |
| NCT06482463University Hospital, ToulouseDiagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis | 2027-02 |
| NCT06643039Hospices Civils de LyonNosocomial Respiratory Virus Infection | 2027-07-05 |
| NCT07822971Centre Hospitalier Régional Metz-ThionvilleImpact of an On-site Simulation-based Training Programme on Adherence to Standard Precautions and Healthcare-associated Infections in Adult Intensive Care | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 47 studies in Cross Infection with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Biofilm is a microstructure organised into aggregates of microbiological species within a polymeric matrix. As early as the 2000s, the Centers for Disease Control and Prevention (CDC) recognised the possible role of the biofilm lining endotracheal endotracheal tubes in the development of ventilator-associated pneumonia (VAP) , the most common infection in intensive care, with a high morbidity and mortality rate and a significant increase in hospital costs.
Targeting biofilm therefore now appears to be a new area of interest for limiting the risk of VAP, and this rationale has led to the development of an intraluminal for abrading biofilm deposited on the inside of the intubation probe
. Evaluation of this type of strategy nevertheless justifies the introduction of more precise methods for characterisation of the biofilm.
To this end, the investigator carried out an initial clinical study describing the biofilm on intubation probes, BIOPAVIR 1, showing the existence of several biofilm structures, each associated with a specific microbiological signature. Several limitations including a lack of power due to an insufficient number of patients and the use of number of patients, and the use of a confocal microscopy technique with poor axial without the possibility of acquiring metabolic images of the biofilm.
Based on the previous description of biofilm by optical coherence tomography (OCT), and a recent experience with an optimised form of high-resolution OCT, called full-field OCT, the investigator hypothesise that full-field OCT will allow more accurate characterisation of biofilm, due to its high spatial resolution and its potential ability to capture metabolic activity in the biofilm BIOPAVIR 2 proposes to use the performance of full-field OCT to better characterise the biofilm lining endotracheal tubes in patients undergoing mechanical ventilation in intensive care units. This project represents a first step towards understanding the link between the development of biofilm on intubation and the occurrence of VAP
Patient over 18 years of age having declared their nonobjection and exposed to mechanical ventilation for at least two calendar days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult critically ill patients (\> 18 years of age) exposed to endotracheal tube for at least two calendar days
Other: •Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube
Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm
Dynamic Full-Field Optical Coherence Tomography-based biofilm structure type
shape data
Time frame: At Day 0, within 72hours following endothracheal tube removal
type of microbiological associated with each shape
Time frame: At Day 0, within 72hours following endothracheal tube removal
Started Mar 2024 (actual). Primary completion is estimated for Mar 2025, 12 months after the start.
Of 57 non-industry observational studies under Cross Infection, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 65. This study's planned 12 months is below that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 14 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire Dijon →